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Introduction
The largest risk of colorectal cancer (CRC) develop-
ment, one of the most frequent malignant tumors in the
industrialized world [1], is observed in patients with
genetic predispositions or with sporadic adenomatous
polyps [2]. The process of colorectal carcinogenesis is
complex and long-term and includes several steps of
malignant transformation from normal epithelium to
cancer cells, which involves numerous genetic
changes and results in various phenotypic alterations
[3]. The colorectal adenomas are neoplastic tumors
with a potential to develop into invasive adenocarcino-
ma of colon or rectum. 
Matrix metalloproteinases (MMPs) are zinc-
dependent endopeptidases which are able to degrad-
ing the components of extracellular matrix. Type IV
collagen is an important protein of basement mem-
brane. Among all the MMPs, only gelatinases, such as
matrix metalloproteinase 2 (MMP-2) and matrix met-
alloproteinase 9 (MMP-9) participate in degradation
of type IV collagen [4-6]. Remodelling of normal and
tumoral tissue may be a result of imbalance between
MMPs and their natural inhibitors – tissue inhibitors
of matrix metalloproteinases (TIMPs). It has been
shown that degradation of basement membrane and
invasion of epithelium is the first step of tumor devel-
opment and metastasis [4]. Matrix metalloproteinase
2 (MMP-2) and tissue inhibitor of matrix metallopro-
teinases 2 (TIMP-2) are involved in tumor invasion
and metastasis including breast, gastric, pancreatic
and colorectal cancer [7-10].
It was shown that MMP-2 gene expression level was
lower in colorectal cancer tissue than in adjacent normal
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Waas et al. showed that plasma MMP-2 levels were
lower in CRC metastatic liver disease than in healthy
controls [12]. However, Wu et al. revealed that expres-
sion of MMP-2 protein significantly increased in CRC
tissues but it was not detected in normal colorectal tis-
sues [13]. 
Li et al. indicated that the balance between MMP-
2 and TIMP-2 might play a crucial role in the process
of colorectal carcinoma invasion and metastasis [14].
They demonstrated that expression of MMP-2 in CRC
tissues was significantly higher, but TIMP-2 – signifi-
cantly lower than in normal tissues. Additionally, they
revealed that MMP-2/TIMP-2 ratio was higher in CRC
than in normal tissues and gradually decreased with
the progression of invasion depth, lymph node metas-
tasis and tumor Duke's stage [14]. 
It is suggested that MMPs and TIMPs might play a
role not only in colorectal tumor invasion and initia-
tion of metastatic cascade, but also in colorectal car-
cinogenesis from adenomatous polyps. The mRNA
and protein expression levels of MMP-2 were investi-
gated in colonic adenoma-carcinoma sequence, ie.
normal colonic tissue, colon adenoma, early colon
cancer and advanced colon cancer tissues collected
from the same subjects [15]. However, little is known
about serum levels of MMP-2 and TIMP-2 in colorec-
tal adenoma and cancer patients. 
Therefore, the aim of the present study was to
investigate the clinical importance of the measurement
of serum levels of MMP-2 and TIMP-2 in patients
with colorectal adenoma and cancer, especially in the
diagnosis of CRC patients as well as in the differenti-
ation between CA and cancer. We determined the con-
centrations of MMP-2 and TIMP-2 in the sera of CRC
patients in relation to clinico-pathological features of
cancer and serum levels of classical tumor markers:
carcinoembryonic antigen (CEA) and carbohydrate
antigen (CA 19 9). Moreover, we assessed the diag-
nostic sensitivity and areas under ROC curves (AUC)
for all the proteins tested as well as their prognostic
significance in CRC patients' survival. 
Material and methods
Patients. The study included a total number of 210 subjects: 91
previously untreated colorectal cancer (CRC) patients (37 women
and 54 men, aged 41-84 years) diagnosed and operated on by
Second General Surgery Department of the Bia³ystok Medical
University Hospital, 28 patients with colorectal adenomas (CA)
(10 women and 18 men, aged 32-78 years) and 91 healthy subjects
(60 women and 31 men, aged 21-65 years). 
The clinical diagnosis of CRC or CAwas confirmed by micro-
scopic examination of the material obtained during colonoscopy
and/or surgery. Eighty-five CRC patients underwent surgical tumor
resection, while six patients had non-resectable tumors. The stag-
ing was based on a routine histopathological analysis and clinical
assessment, according to Duke's classification. The tumors were
classified in accordance with the staging of the 5th International
Union Against Cancer [16]. The subjects who had suffered a heart
attack or heart failure were not included in the study. Moreover, the
patients with extraintestinal tumors and those after preoperative
radio-chemotherapy were excluded from the study.
For the analysis, the CRC patients were divided into five
groups: 2 cancer patients in stage A, 5 patients in stage B1, 
30 patients in stage B2, 25 patients in stage C1, 4 patients in stage
C2, and 25 patients in stage D, and then sub-divided into: four
groups depending on the infiltration of the bowel wall (T1, T2, T3,
and T4), four groups depending on nodal involvement (N0, N1, N2
and N3), two groups depending on the presence of distant metas-
tases (M0 and M1). The number of patients in the analyzed sub-
groups is shown in Table 1. 
Protein analyses. Blood samples from all the patients were drawn
before surgery or polypectomy. None of the CRC patients had
received chemo- or radiotherapy before blood sample collection.
To standardize clotting conditions, all sera were separated within 
1 hour after blood collection and stored at -80°C until assayed. 
Serum levels of MMP-2 and TIMP-2 were measured using
enzyme-linked immunosorbent assay kits (ELISA) (R&D Sys-
tems, Abingdon, England) according to the manufacturer's instruc-
tions. The serum samples were diluted 10-fold before determina-
tion of MMP-2 and 50-fold before measurement of TIMP-2. The
intra-assay coefficient of variation (CV%) of MMP-2 is reported
by the manufacturer to be 5.8% at a mean concentration of 
18.9 ng/mL, SD=1.1 and of TIMP-2 – to be 4.4% at a mean con-
centration of 1.23 ng/mL, SD=0.054. 
Serum concentrations of CEA and CA 19-9 were measured by
microparticle enzyme immunoassay kits (MEIA) (Abbott, Chica-
go, Illinois). The intra-assay CV for CEA is reported by the manu-
facturer of the assay kits to be 4.9% at a mean concentration of 2.2
ng/mL, SD=0.11 and the intra-assay CV% for CA 19-9 – 4.7% at
a mean concentration of 38.2 IU/mL, SD=1.80. 
The cut-off points for serum levels of MMP-2 (160 ng/mL) and
TIMP-2 (85 ng/mL) were determined using Microsoft Office Excel
software. In the ROC report generated by this program, the cut-off
values corresponded to the highest accuracy (minimal false-negative
and false-positive results). The positive results of MMP-2 and TIMP-
2 are below cut-off values. The reference cut-off values for tumor
markers (the 95th percentile) were established previously in our
department by examining blood sera of healthy volunteers [17]. The
cut-off points were 4.0 ng/mL for CEAand 30.0 IU/mL for CA19-9.
Ethical issues. The study was approved by the local ethics com-
mittee. All the patients gave their informed consent to participate
in the study. 
Statistical analysis. A preliminary statistical analysis (χ2 test)
revealed that serum levels of MMP-2, TIMP-2, CEAand CA19-9 did
not follow a normal distribution. Therefore, nonparametric statistical
analyses were used. The stages A, B1 and B2 were analyzed as one
group (stage A+B) whereas stages C1 and C2 – as stage C because of
small numbers of patients in the particular subgroups. Similarly, the
T1 and T2 patients were analyzed as T1+T2 subgroup. 
The Mann-Whitney U-test was used to compare the two groups
in each category (colon versus rectal cancer; M0 versus M1 group;
resectable tumors versus nonresectable; the group of patients who
survived versus patients who died of CRC). Differences between
more than two groups (e.g. CRC, CA and healthy controls; stage
A+B, C, D; or T1+T2, T3, T4; or N0, N1, N2, N3) were compared
using ANOVA on ranks (Kruskal-Wallis tests). When significant
differences were found, the post hoc Dwass-Steele-Critchlow-
Fligner test was conducted to determine which groups were differ-
ent. The Spearman rank correlation test was employed for the cor-
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method of Kaplan and Meier. Univariate analyses of survival were
performed using the log-rank test, and multivariate analyses
employed Cox's proportional hazards model. For all multivariate
analyses, forward stepwise procedures were used. Differences
were considered statically significant with p values below 0.05.
Moreover, we calculated diagnostic criteria, such as percentage
of true positive levels (diagnostic sensitivity) and area under the
receiver operating characteristic (ROC) curve (AUC) for the
MMP-2, TIMP-2 and tumor markers. Statistical analyses were car-
ried out using the STATISTICA 9.0 PL program (StatSoft Inc.,
Tulsa, OK). Diagnostic criteria and the ROC curves were calculat-
ed using Med-Calc statistical software (MedCalc Software, Mari-
akerke, Belgium) and Microsoft Office Excel program (Microsoft
Corporation, Redmond, WA).
Results
Serum levels of MMP-2, TIMP-2, CEA and CA
19-9 in colorectal cancer and colorectal adeno-
ma patients
Concentrations of MMP-2, TIMP-2 and tumor mark-
ers in the sera of colorectal cancer and adenoma
patients as well as in healthy subjects are presented in
Table 2. Serum levels of MMP-2 and TIMP-2 were
lower, but CEA and CA 19-9 higher in CRC patients
than in CA patients and healthy controls. Moreover,
levels of MMP-2 and TIMP-2 were lower and tumor
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Fig. 1. Percentage of true positive
results of MMP-2, TIMP-2 and
tumor markers in colorectal cancer
patients
Fig. 2.Areas under ROC curves for CEA(AUC=0.8473), TIMP-2
(AUC=0.7097), MMP-2 (AUC=0.6941) and CA19-9
(AUC=0.6824) in differentiation between colorectal cancer
patients and healthy subjects
Fig. 3. Areas under ROC curves for CEA(AUC=0.7993), MMP-2
(AUC=0.6709), CA19-9 (AUC=0.5893) and TIMP-2
(AUC=0.5165) in differentiation between colorectal cancer and
colorectal adenoma patientsmarkers higher in adenoma group in comparison with
control group. The differences between analyzed
groups were significant for all proteins tested in
Kruskal-Wallis test. Additionally, the differences
between groups were confirmed in Dwass-Steel-
Critchlow-Fligner post hoc tests and statistical signifi-
cance was found for comparison of all proteins tested
in CRC patients and healthy controls, but for MMP-2
and CEA – in comparison of CRC group with CA
patients. The concentrations of MMP-2 and TIMP-2 in
patients with colonic cancer were lower, but levels of
tumor markers higher than those in rectal cancer sub-
group, although the differences were not significant. 
Concentrations of MMP-2 and TIMP-2 correlated
with tumor stage and were the lowest in the sera of
CRC patients with stage D, but serum levels of tumor
markers increased and the highest values were
observed in patients with most advanced cancer. The
differences between cancer stages were significant
only for CA 19-9 in Kruskal-Wallis test (p=0.027) and
were confirmed in post hoc Dwass-Steel-Critchlow-
Fligner test for comparison between patients with
Duke's stage C and D of CRC patients.
Serum levels of MMP-2, TIMP-2, CEA and CA
19-9 in CRC patients in relation to clinico-
pathological features of tumor
Table 3 presents concentrations of MMP-2, TIMP-2,
CEA and CA 19-9 in the sera of CRC patients in rela-
tion to clinico-pathological variables of tumor. Serum
levels of all proteins tested varied according to bowel
wall infiltration (T factor). Concentrations of MMP-2
and TIMP-2 were the lowest but tumor markers the
highest in the T4 subgroup, although these differences
were not significant. Similar results were observed in
serum levels of MMP-2 in relation to nodal involve-
ment – the lowest values were observed in patients with
the highest number of metastatic lymph nodes (N3 sub-
group), but the differences did not reach statistical sig-
nificance. In patients with distant metastases (M1 sub-
group) concentrations of CEA and CA 19-9 increased
significantly in comparison with M0 subgroup
(p=0.017 nad 0.019, respectively). The concentrations
of MMP-2 and TIMP-2 revealed an inverse tendency –
they decreased in M1 patients, but the differences were
not significant in Mann-Whitney test. Moreover, serum
levels of MMP-2 and TIMP-2 were lower in CRC
patients with nonresectable tumors compared to those
with resectable. Similar observations were made in
subgroup of CRC patients who died of cancer during
observation period, although the differences were not
statistically significant. These findings were confirmed
in Spearman rank correlation test, where concentrations
of MMP-2 significantly correlated with serum levels of
TIMP-2 but CEA with CA 19-9. 
The diagnostic criteria for MMP-2, TIMP-2,
CEA and CA 19-9 in CRC patients
The percentage of true positive results of proteins test-
ed in CRC patients (diagnostic sensitivity) is presented
in Fig. 1. The diagnostic sensitivity of serum TIMP-2
levels (59%) was higher than those of MMP-2 (46%),
CEA(43%) and CA19-9 (18%). The frequency of true
positive results was the highest for the combination of
CEA with TIMP-2 (79%). The TIMP-1 area under
ROC curve (AUC) for differentiation between CRC
and healthy subjects (0.7097) was higher than AUC for
MMP-2 (0.6941) and CA 19-9 (0.6824) but lower than
for CEA (0.8473) (Fig. 2). Additionally, we analyzed
AUC for differentiation between CRC and CApatients.
The highest values were obtained for CEA(0.7993) and
MMP-2 (0.6709) (Fig. 3). 
567 MMP-2 and TIMP-2 in colorectal cancer and adenoma
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2010:48(4): 567 (564-571) 
Doi: 10.2478/v10042-010-0076-1
Table 1. Characteristics of colorectal cancer patientsCorrelations between MMP-2, TIMP-2 CEA
and CA 19-9 serum levels and prognosis of
patients' survival
Univariate analysis showed that tumor stage
(p=0.012), presence of nodal (p=0.015) and distant
metastases (p=0.003), tumor resectability (p=0.001)
and serum levels of CEA (p=0.007) and CA 19-9
(p=0.007) were significant factors affecting overall
survival. Age and gender of colorectal cancer patients
as well as tumor size (T factor) and concentrations of
MMP-2 and TIMP-2 were not significant prognostic
factors. Multivariate regression analysis with Cox's
proportional hazard model revealed that only tumor
resectability was an independent prognostic factor for
the survival of CRC patients (p=0.019).
Discussion
Matrix metalloproteinases, the enzymes involved in
mechanisms of tumor progression and formation of dis-
tant metastases, may be synthesized by neoplastic and
stromal cells [4]. Natural tissue inhibitors of matrix
metalloproteinases – TIMPs are induced in stromal
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Table 2. Serum levels of MMP-2, TIMP-2 and tumor markers in colorectal cancer and adenoma patients 
* statistically significant when p<0.05 
Table 3. Serum levels of MMP-2, TIMP-2 and tumor markers in colorectal cancer patients in relation to clinicopathological features of
tumor
* statistically significant when p<0.05
A- statistically significant when compared to healthy controls in Dwass-Steel-Critchlow-Fligner post hoc test
B- statistically significant when compared to colorectal adenomas in Dwass-Steel-Critchlow-Fligner post hoc test 
C- statistically significant when compared to stage C in Dwass-Steel-Critchlow-Fligner post hoc test cells to regulate the reactions of these proteinases [18].
It was suggested that the enhanced cell surface expres-
sion of MMPs and TIMPs on inflammatory cells in
cancer tissue might be a result of a host response
induced by tumors [19]. Increased expression of MMP-
2 might play a key role in colorectal cancer invasion
and/or metastasis [20,21]. Moreover, it was shown that
in colon and rectal tumor tissues MMP-2 protein levels
were higher, while TIMP-2 significantly lower than in
corresponding paired normal mucosa [22]. 
So far, in contrast to tissue expression, little is
known about concentrations of MMP-2 and TIMP-2 in
the blood of CRC patients. Therefore, this report aims
to examine the clinical importance of the measurement
of pretreatment serum levels of MMP-2 and TIMP-2 in
patients with colorectal adenoma and cancer, especial-
ly in the diagnosis of CRC patients as well as in the
differentiation between CA and cancer. The classic
tumor markers for CRC – CEA and CA 19-9, which
are currently used as biomarkers of tumor burden in
clinical practice, were used as reference markers. 
In the present study, the preoperative serum levels of
CEA and CA 19-9 were significantly higher in colorec-
tal cancer group than in healthy subjects, what is in
accordance with our previous results [23]. On the con-
trary, the serum levels of MMP-2 and TIMP-2 in CRC
patients were significantly lower than in healthy sub-
jects. The obtained results are in line with the investiga-
tion of Waas et al., who showed that plasma pro-MMP-
2 levels were lower in colorectal cancer patients than in
healthy controls [24]. Moreover, in the study of Oberg
et al., the serum level of the MMP-2/TIMP-2 complex
was significantly lower in CRC patients as compared to
healthy blood donors. However, the serum levels of free
MMP-2 and total amount of TIMP-2 were significantly
higher in comparison with control group [25]. Addition-
ally, Gehrstein et al. showed the increased content of
MMP-2 in tumors in 70-90% patients with colorectal
cancer in comparison with the adjacent normal mucosa,
although in their study content of TIMP-2 in tumors did
not increase at the level of statistic significance as well
as plasma concentrations of both proteins did not corre-
late with the corresponding values in the tumors and did
not surpass the normal levels [26]. It may suggest that in
CRC development occur an imbalance between MMP-
2 and TIMP-2.
In our study, the serum levels of MMP-2 and
TIMP-2 correlated with tumor stage and were the low-
est in stage D of cancer, what is in agreement with the
results obtained by Larsen et al., who revealed that
TIMP-2 concentration in EDTA plasma from CRC
patients with Dukes stage A were significantly higher
in comparison with more advanced tumor stages [27].
Li  et al. demonstrated that with the progression of
tumor Duke's stage, the MMP-2/TIMP-2 ratio
decreased, suggesting that the balance between MMP-
2 and TIMP-2 plays a crucial role in the invasion of
CRC [14]. Additionally, in our paper the serum MMP-
2 and TIMP-2 levels in CRC patients decreased with
bowel wall infiltration (T factor), nodal involvement
(N factor) and presence of distant metastases (M fac-
tor), as well as in nonresectable tumors, although the
differences were not significant. This tendency is
opposite to the results of Angenete et al. who revealed
that plasma levels of MMP-2 were higher in CRC
patients with distant metastases [28]. However, our
findings are in accordance with the study of Langen-
skiöld et al. who found that plasma MMP-2 in CRC
patients with T4 tumors was lower than in T3 and T2
subgroups [29]. The decrease of serum MMP-2 and
TIMP-2 in more advanced tumor stages might reflect
formation of MMP-TIMP complexes in colorectal
tumor progression. The obtained results suggest that
use of MMP-2 and TIMP-2 might be a predicting tool,
especially in combination with different imaging tech-
niques, which might give important preoperative infor-
mation in staging patients with colorectal cancer. 
We also investigated whether the serum concentra-
tions of MMP-2 and TIMP-2 might be useful prognos-
tic factors for CRC patients' survival. The univariate
analysis showed that only classic tumor markers,
tumor stage, N and M factors as well as tumor
resectability were significant prognostic factors in
CRC patients. Consequently, all these variables
included in the multivariate regression analysis,
revealed that only tumor resectability may be an inde-
pendent prognostic factor of CRC patients' survival.
Our results are in agreement with those of Waas et al.,
who showed that the preoperative plasma proMMP-2
levels have no potential value as prognostic markers in
CRC. However, they did not investigate the prognostic
significance of TIMP-2 [12]. 
In the present paper, we defined the diagnostic sen-
sitivity and area under ROC curve (AUC) for all the
proteins tested to assess a potential clinical signifi-
cance of MMP-2 and TIMP-2 as tumor markers in the
diagnosis of CRC. We revealed that the percentage of
true positive results (diagnostic sensitivity) of TIMP-2
(59%) and MMP-2 (46%) were higher than frequency
of elevated levels of both tumor markers (CEA– 43%,
CA19-9 – 18%). The diagnostic sensitivity of proteins
tested was highest for TIMP-2 with CEA (79%) and
much higher than for combined use of classical tumor
markers for CRC – CEA with CA 19-9 (49%). 
The analysis of ROC curves indicates the advantage
of TIMP-2 measurement over assessment of classical
tumor marker – CA 19-9 in colorectal cancer patients.
We found that AUC for TIMP-2 measurement (0.7097)
was higher than for MMP-2 – 0.6941 and CA 19-9 –
0.6824 but lower than for CEA (0.8473) in differentia-
tion between CRC patients and healthy subjects. The
results for CEA and CA 19-9 are similar to those
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fulness of classical tumor markers in CRC patients [23].
Additionally, in our study the clinical significance of
serum MMP-2 and TIMP 2 in the differentiation
between colorectal adenoma and cancer was assessed in
the analysis of area under ROC curve for these proteins.
The value obtained for MMP-2 (0.6709) was higher
than for CA 19-9 and TIMP-2, although lower than for
CEA (0.7993) These results suggest a potential clinical
usefulness of pretreatment serum MMP-2 for the differ-
entiation between malignant and non-malignant tumors. 
In conclusion, the aim of the present study was to
investigate the clinical importance of the measure-
ment of serum levels of MMP-2 and TIMP-2 in
patients with colorectal adenoma and cancer, espe-
cially in the diagnosis of CRC patients as well as in
the differentiation between CA and cancer. We
assessed that serum levels of these proteins were
lower in CRC patients than in healthy subjects. More-
over, serum MMP-2 was significantly lower in
patients with CRC than in colorectal adenoma
patients. The percentage of true positive results of
serum TIMP-2 was higher than those of other mea-
surands and increased in combined use with CEA.
Additionally, the AUC of TIMP-2 was larger than
that of MMP-2 in differentiation between CRC and
healthy subjects but MMP-2 area was bigger than
AUC of tissue inhibitor of matrix metalloproteinases
2 in differentiation between colorectal cancer and
adenoma. Our results indicate the better usefulness of
TIMP-2 than MMP-2 in the diagnosis of colorectal
cancer, especially in combined use with classic tumor
marker of CRC, e.g. CEA. Serum MMP-2 seems to
be a better tumor marker than TIMP-2 in the differ-
entiation between colorectal cancer and adenoma
patients. However, due to discrepancies between the
correlation of MMP-2 and TIMP-2 levels with clini-
co-pathological features of tumor and patients' sur-
vival, these findings require further studies.
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